Neratinib was granted marketing authorization by the European Commission in 2018 and is indicated for extended adjuvant treatment of adult patients with early-stage hormone receptor-positive HER2-overexpressed/amplified breast cancer who are less than 1 year from the completion of prior adjuvant trastuzumab-based therapy [46]. This evidence concerns the gene NR4A1 and breast carcinoma.